What's in Mundipharma Research Limited's pipeline?

Mundipharma Research Limited has 18 drugs in our index: 1 marketed, 0 filed, 7 in Phase 3, 1 in Phase 2, 9 in Phase 1.

Which companies overlap with Mundipharma Research Limited's portfolio?

Top competitors by shared drug class: Milton S. Hershey Medical Center, AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme LLC, SkyePharma AG.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mundipharma-research-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Mundipharma Research Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mundipharma Research Limited pipeline: 1 marketed, 0 filed, 7 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 7 Phase 3 1 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Flixotide	Flixotide	marketed		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	Oncology
Flutiform 50/5 micrograms	Flutiform 50/5 micrograms	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)	Respiratory/Pulmonology
Rezafungin for Injection	Rezafungin for Injection	phase 3	Echinocandin antifungal	1,3-beta-D-glucan synthase	Infectious Disease
Flutiform 250/10 micrograms	Flutiform 250/10 micrograms	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor; beta-2 adrenergic receptor	Respiratory/Pulmonology
Flixotide plus Foradil	Flixotide plus Foradil	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (fluticasone); Beta-2 adrenergic receptor (formoterol)	Respiratory/Pulmonology
Flutiform	Flutiform	phase 3			Other
Flixotide pMDI 250 micrograms	Flixotide pMDI 250 micrograms	phase 3	Inhaled corticosteroid	Glucocorticoid receptor	Respiratory / Pulmonology
Fluticasone/formoterol BAI	Fluticasone/formoterol BAI	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)	Respiratory/Pulmonology

Therapeutic area mix

Respiratory/Pulmonology · 4
Infectious Disease · 1
Oncology · 1
Other · 1
Respiratory / Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Milton S. Hershey Medical Center · 2 shared drug classes
AstraZeneca · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
SkyePharma AG · 2 shared drug classes
Chiesi Farmaceutici S.p.A. · 2 shared drug classes
Centre Hospitalier Universitaire, Amiens · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mundipharma Research Limited:

Cite this brief

Drug Landscape (2026). Mundipharma Research Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mundipharma-research-limited. Accessed 2026-05-17.